BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Craxì L, Cammà C, Craxì A. HCV: the best cure possible or the best possible cure? J Viral Hepat 2015;22:627-9. [PMID: 26135025 DOI: 10.1111/jvh.12411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
2 O'Malley PA. The Ethics, Cost, and Evidence Surrounding Current Pharmacological Treatment of Hepatitis C Virus Infection. Clin Nurse Spec 2017;31:186-8. [PMID: 28594667 DOI: 10.1097/NUR.0000000000000311] [Reference Citation Analysis]
3 Marcellusi A, Viti R, Damele F, Cammà C, Taliani G, Mennini FS. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective? Clin Drug Investig 2016;36:661-72. [DOI: 10.1007/s40261-016-0414-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yaya I, Roux P, Marcellin F, Wittkop L, Esterle L, Spire B, Dominguez S, Elegbe BA, Piroth L, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. PLoS One 2018;13:e0199874. [PMID: 29975764 DOI: 10.1371/journal.pone.0199874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]